Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) represents the hemicalcium hydrate form of the calcium salt of Orforglipron, an orally active agonist targeting the Glucagon-like peptide-1 receptor (GLP-1R). This compound has demonstrated efficacy in mitigating type 2 diabetes [1].

Orforglipron hemicalcium hydrate effectively inhibits food intake in cynomolgus monkeys, promotes insulin secretion, and reduces blood glucose levels when administered in a dose-dependent manner. In these models, doses of 0.05-1.35 mg/kg achieved peak plasma concentration (C max) approximately 2 hours post-administration, showing near-proportional increases in plasma exposure with dose. Pharmacokinetic analysis details the absorption process through the gastrointestinal tract, indicating dose-dependent characteristics. The compound was continuously administered intravenously for 30 minutes or via gavage for 5 days at specific concentrations, resulting in improved metabolic outcomes.